Personalis completed a $33 million Series C round, led by Lightspeed Venture Partners, bringing its total capital raised to $75 million. All of the Series A investors also participated in the financing, including Abingworth and Mohr Davidow Ventures.

The company provides researchers and clinicians with advanced genome-scale sequencing and interpretation services for inherited genetic disease and cancer. It operates the CLIA licensed and CAP accredited clinical laboratory.

“We have had a very positive response to our new offerings in cancer genomics, especially from pharmaceutical customers, and our Mendelian genetic testing business continues to grow,” said John West, CEO of Personalis. “We find that customers are becoming more sophisticated in understanding the limitations of off-the-shelf next-generation sequencing and analysis tools. They increasingly appreciate that our technology provides them with meaningfully better clinical interpretation.”